SteveGrenard
Philosopher
- Joined
- Oct 6, 2002
- Messages
- 5,528
The abstract states that this is the British Journal of Pharmacology, not the British Journal of Medicine. Both the Lancet and The BMJ have a tradition of open minded publication, placing both sides of the debate in front of their readers. I was not aware that the British J of Pharmacology did also.
I agree that the full paper needs to be read and evaluated. I am not criticising it, I am asking questions or pointing out questions, the answers to which could have possibly skewered the results. I don't know the answers which I why I asked them. In the meantime all we KNOW is what is given in the abstract.
Here is the abstract as it appears in MedLine. Correct me if I am wrong.
We do NOT know what the proofs are: fever, hyperexia, cardiac arrest, tachycardia, flushing, etc. The only proof I found in the historical literature was for Scarlet Fever which correlates with fever and flushing. Or whether any of the proofs include the less well defined effects of belladona which are psychoactive and hallucinogenic.
These results indicate no significance in the proving rate which are both at about 14% for symptoms and 86%, therefore, for nothing.
Br J Clin Pharmacol. 2003 Nov; 56(5): 562-8. Related Articles, Links
Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C.
Brien S, Lewith G, Bryant T.
Complementary Medicine Research Unit, University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK. s.brien@soton.ac.uk
AIMS: To investigate if ultramolecular homeopathy has any clinical effects. This was assessed using the proving of the homeopathic remedy Belladonna given at an ultramolecular dose (30C), as a model. A proving states that when a homeopathic remedy is given to a healthy person, they will experience symptomatic effects specific to that remedy. If ultramolecular doses are clinically active, the Belladonna 30C group should experience more true Belladonna proving symptoms than the placebo group. METHODS: Healthy subjects (n = 253), aged 18-30 years, took part in this double-blind, randomized placebo-controlled study. Total study duration was 4 weeks. Subjects were randomized before 1 week placebo run-in. They received 2 weeks of treatment intervention (Belladonna 30C or placebo) and were followed up for 1 week. Subjects recorded any symptoms experienced during the total study period on a daily basis using a structured questionnaire. Symptom diaries were analysed blind to determine if each subject had proved or not (based on predefined criteria). The main outcome was the proportion of subjects who had proved in each treatment group. RESULTS: No significant group differences in proving rates were observed [Belladonna provers N = 14 (13.9%); placebo provers N = 15 (14.3%); mean difference -0.4%, 95% confidence interval -9.3, 10.1] based on intention to treat analysis. Primary outcome was not affected by seasonality or the individual's attitude to complementary medicine. CONCLUSION: Ultramolecular homeopathy had no observable clinical effects.
PMID: 14651731 [PubMed - in process]
I agree that the full paper needs to be read and evaluated. I am not criticising it, I am asking questions or pointing out questions, the answers to which could have possibly skewered the results. I don't know the answers which I why I asked them. In the meantime all we KNOW is what is given in the abstract.
Here is the abstract as it appears in MedLine. Correct me if I am wrong.
We do NOT know what the proofs are: fever, hyperexia, cardiac arrest, tachycardia, flushing, etc. The only proof I found in the historical literature was for Scarlet Fever which correlates with fever and flushing. Or whether any of the proofs include the less well defined effects of belladona which are psychoactive and hallucinogenic.
These results indicate no significance in the proving rate which are both at about 14% for symptoms and 86%, therefore, for nothing.
Br J Clin Pharmacol. 2003 Nov; 56(5): 562-8. Related Articles, Links
Ultramolecular homeopathy has no observable clinical effects. A randomized, double-blind, placebo-controlled proving trial of Belladonna 30C.
Brien S, Lewith G, Bryant T.
Complementary Medicine Research Unit, University of Southampton, Royal South Hants Hospital, Brintons Terrace, Southampton SO14 0YG, UK. s.brien@soton.ac.uk
AIMS: To investigate if ultramolecular homeopathy has any clinical effects. This was assessed using the proving of the homeopathic remedy Belladonna given at an ultramolecular dose (30C), as a model. A proving states that when a homeopathic remedy is given to a healthy person, they will experience symptomatic effects specific to that remedy. If ultramolecular doses are clinically active, the Belladonna 30C group should experience more true Belladonna proving symptoms than the placebo group. METHODS: Healthy subjects (n = 253), aged 18-30 years, took part in this double-blind, randomized placebo-controlled study. Total study duration was 4 weeks. Subjects were randomized before 1 week placebo run-in. They received 2 weeks of treatment intervention (Belladonna 30C or placebo) and were followed up for 1 week. Subjects recorded any symptoms experienced during the total study period on a daily basis using a structured questionnaire. Symptom diaries were analysed blind to determine if each subject had proved or not (based on predefined criteria). The main outcome was the proportion of subjects who had proved in each treatment group. RESULTS: No significant group differences in proving rates were observed [Belladonna provers N = 14 (13.9%); placebo provers N = 15 (14.3%); mean difference -0.4%, 95% confidence interval -9.3, 10.1] based on intention to treat analysis. Primary outcome was not affected by seasonality or the individual's attitude to complementary medicine. CONCLUSION: Ultramolecular homeopathy had no observable clinical effects.
PMID: 14651731 [PubMed - in process]
